Takeda
As of the edition of 20 October 2026, Takeda runs 252 drugs, 110 of them marketed; it is on route A at 32 targets and on route B at 49 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Takeda was renamed in 2019.
The records place 20 company names in this family.
- Millennium Pharmaceuticals, Inc.: acquired in 2008; successor 501 Takeda Chemical Industries, Ltd.
- Ariad Pharmaceuticals, Inc.: acquired in 2017; successor 501 Takeda Chemical Industries, Ltd.
- Baxalta Incorporated: acquired in 2019; successor 501 Takeda Chemical Industries, Ltd.
- Shire Development Inc: acquired in 2019; successor 501 Takeda Chemical Industries, Ltd.
- 501 Takeda Chemical Industries, Ltd.: renamed in 2019
- Baxalta now part of Shire: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 110 |
| Active | 24 |
| Went quiet | 45 |
| Stopped | 61 |
| Withdrawn from market | 1 |
| Status not established | 11 |
| Total | 252 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Metformin | none listed | 4 |
| Bortezomib | none listed | 1 |
| Aspirin | none listed | 8 |
| Midazolam | none listed | 1 |
| Amoxicillin | none listed | 0 |
| Amlodipine | none listed | 16 |
| Prednisolone | none listed | 6 |
| Budesonide | Ends 2029 (exclusivity) | 5 |
| Pioglitazone | none listed | 2 |
| Methylphenidate | none listed | 11 |
| Leuprolide | Ended 2026 (exclusivity) | 1 |
| Hydrocortisone | none listed | 5 |
| Ondansetron | none listed | 0 |
| Cabozantinib | Ends 2032 (exclusivity) | 2 |
| Hydrochlorothiazide | none listed | 4 |
| Metronidazole | none listed | 0 |
| Clarithromycin | none listed | 0 |
| Panitumumab | Ended 2018 (computed from the first US licence) | 1 |
| Niraparib | Ends 2031 (patent) | 6 |
| Colchicine | none listed | 8 |
| Human immunoglobulin g | Ended 2015 (orphan exclusivity) | 0 |
| Brentuximab vedotin | Ends 2029 (orphan exclusivity) | 10 |
| Levodopa | none listed | 4 |
| Fruquintinib | Ends 2035 (patent) | 2 |
| Pantoprazole | Ends 2027 (exclusivity) | 1 |
A route B row is one company at one target. 85 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 32 targets, route B at 49 targets.
All 81 rows on route A or B
In the product81 company-target rows on route A or B; 78 are not shown here, and no score is.
See all 81 targets where Takeda needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 165 trials led
- Nutrition and metabolism: 131 trials led
- Blood and lymph: 127 trials led